# A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants

> **NCT01866033** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 8 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** PCI-32765 (Treatment A)
- **DRUG:** PCI-32765 (Treatment B)
- **DRUG:** PCI-32765 (Treatment C)
- **DRUG:** 13C6 PCI-32765 (reference)

## Key facts

- **NCT ID:** NCT01866033
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2014-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01866033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01866033, "A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01866033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*